[1] |
Ferlay J,Soerjomatam I,Dikshit R,et al.Cancer incidence andmortalityworldwide:sources,methods andmajor patterns in GLOBOCAN 2012[J].Int JCancer,2015,136(5):E359-386.
|
[2] |
NaginiS.Carcinomaof the stomach:A review ofepidemiology,pathogenesis molecular genetics and chemoprevention[J]. World JGastrointest Oncol,2012,4(7):156-169.
|
[3] |
张慧卿,何波,万以叶.晚期胃癌二线化疗的研究现状[J].实用癌症杂志,2014,29(1):117-119.
|
[4] |
Andoh H,McNulty NJ,Lewis PJ.Improving accuracy in reporting CT scans of oncology patients:assessing the effect of education and feedback interventions on the application of the Response Evaluation Criteria in Solid Tumors (RECIST)criteria[J].Acad Radiol,2013,20(3):351-357.
|
[5] |
孙燕.内科肿瘤学[M].北京:人民卫生出版社,2007:994-995.
|
[6] |
周燕燕,席淑华.胃大部切除术后3年胃癌患者生活质量的EORTCQLQ-C 30与QLQ-STO 22联合评价[J].世界华人消化杂志,2012,20(19):1782-1786.
|
[7] |
Izuishi K,Mori H.Recent strategies for treating stage IV gastric cancer:rolesofpalliative gastrectomy,chemotherapy,and radiotherapy[J].JGastrointestin Liver Dis,2016,25(1):87-94.
|
[8] |
李晟,陆建伟.晚期胃癌化疗的历史和现状[J].中国肿瘤外科杂志,2011,3(1):39-42.
|
[10] |
玛依努尔·艾力,郑超,包泳星,等.DCF方案治疗晚期胃癌患者的临床分析[J].现代肿瘤医学,2011,19(5):966-967.
|
[11] |
骆梅青,康马飞,廖漓漓.DF和DCF方案治疗晚期胃癌的临床对比研究[J].现代肿瘤医学,2011,19(3):511-513.
|
[18] |
董宁宁,王明玉,张琼,等.奥沙利铂联合卡培他滨一线治疗进展期胃癌的临床疗效观察[J].癌症,2009,28(4):412-415.
|
[9] |
Van Cutsem E,Moiseyenko VM,Tjulandin S,et al,PhaseⅢstudy of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a reportof the V 325Study Group[J]. JClin Oncol,2006,24(31):4991-4997.
|
[12] |
Unek IT,Akman T,Oztop I,et al.Bimonthly regimen of high-dose leucovorin,infusional 5-fluorouracil,docetaxel,and cisplatin(modified DCF)in advanced gastric adenocarcinoma[J].Gastric Cancer,2013,16(3):428-434.
|
[13] |
Ajani JA,Fodor MB,Tjulandin SA,et al.PhaseⅡmultiinstitutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated,advanced gastric,or gastroesophageal adenocarcinoma[J].J Clin Oncol,2005,23(24):5660-5667.
|
[14] |
Wang J,Xu R,Li J,et al.Randomizedmulticenter phaseⅢstudy ofamodified docetaxeland cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as firstline therapy for advanced or locally recurrent gastric cancer[J].Gastric Cancer,2016,19(1):234-244.
|
[15] |
Chi Y,Ren JH,Yang L,et al.PhaseⅡclinical study on the modified DCF regimen for treatment of advanced gastric carcinoma[J].Chin Med J(Engl),2011,124(19):2997-3002.
|
[16] |
Bolke E,Peiper M,Budach W.Capecitabine and oxaliplatin for advanced esophagogastric cancer[J].N Engl J Med,2008,358(18):1965.
|
[17] |
Kim YS,Sym SJ,Park SH,et al.A randomized phaseⅡstudy ofweekly docetaxel/cisplatin versusweekly docetaxel/ oxaliplatin as first-line therapy for patients with advanced gastric cancer[J].Cancer Chemother Pharmacol,2014,73 (1):163-169.
|
[19] |
韦淑贞,张闯,朱婧妮,等.奥沙利铂联合卡培他滨一线治疗进展期胃癌疗效观察[J].现代肿瘤医学,2014,22(1):118-120.
|
[20] |
Yang T,Shen X,Tang X,et al.PhaseⅡtrial of oxaliplatin plus oral capecitabine as first-line chemotherapy for patients with advanced gastric cancer[J].Tumori,2011,97 (4):466-472.
|
[21] |
Kuo YC,Liu HT,Lin YL,etal.Modified biweekly oxaliplatin and capecitabine foradvanced gastric cancer:a retrospective analysis from amedical center[J].Biomed J,2014,37(3):141-146.
|
[22] |
XiangXJ,Zhang L,Qiu F,etal.AphaseⅡstudyofcapecitabine plusoxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer[J].Chemotherapy,2012.,58 (1):1-7.
|
[23] |
张昉,陈雅敏,荆超,等.改良DCF方案与FOLFOX 4方案治疗晚期胃癌的临床疗效[J].临床肿瘤学杂志,2014,19(3):231-234.
|
[24] |
尹洪岩,石燕,吴志勇,等.改良DCF与XELOX方案治疗老年晚期胃癌的疗效及安全性分析[J].中国药物应用与监测,2016,13(2):69-73.
|
[25] |
李开春,王静文,唐曦.从循证医学看老年晚期胃癌一线化疗的选择[J].中国肿瘤,2015,(4):314-318.
|